Ipsen SA (IPSEY), a specialty-care biopharmaceutical company, Wednesday reported sales of 918.8 million euros for the first quarter, 11.7 percent higher than the same quarter a year ago.
For fiscal 2025, the company expects sales to grow 5 percent at constant currency.
In 2025, Ipsen anticipates key milestones including regulatory decision on Cabometyx in the European Union for advanced pancreatic and extra-pancreatic neuroendocrine tumors; readout of the Phase 2b study of fidrisertib in fibrodysplasia ossificans progressive; and Proof-of-concept data readout of long-acting neurotoxin, LANT.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.